Conatus Pharmaceuticals Company Profile (NASDAQ:CNAT)

About Conatus Pharmaceuticals

Conatus Pharmaceuticals logoConatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CNAT
  • CUSIP:
Key Metrics:
  • Previous Close: $5.25
  • 50 Day Moving Average: $4.85
  • 200 Day Moving Average: $2.78
  • 52-Week Range: $1.45 - $6.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.56
  • P/E Growth: -0.11
  • Market Cap: $132.16M
  • Outstanding Shares: 25,173,000
  • Beta: 1.34
Profitability:
  • Return on Equity: -87.43%
  • Return on Assets: -75.63%
Debt:
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 8.13%
  • Quick Ratio: 8.13%
Additional Links:
Companies Related to Conatus Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Conatus Pharmaceuticals (NASDAQ:CNAT) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.80 (181.90% upside)

Analysts' Ratings History for Conatus Pharmaceuticals (NASDAQ:CNAT)
Show:
DateFirmActionRatingPrice TargetDetails
12/23/2016SunTrust Banks, Inc.Reiterated RatingBuy$17.00 -> $26.00View Rating Details
12/20/2016FBR & CoSet Price TargetBuy$16.00View Rating Details
12/20/2016Stifel NicolausBoost Price TargetBuy$5.00 -> $7.00View Rating Details
12/20/2016HC WainwrightBoost Price TargetBuy$9.00 -> $18.00View Rating Details
11/9/2016JMP SecuritiesReiterated RatingBuyView Rating Details
10/4/2016Brean CapitalReiterated RatingBuy$7.00View Rating Details
7/1/2016Roth CapitalInitiated CoverageBuy -> BuyView Rating Details
9/24/2015Piper Jaffray CompaniesReiterated RatingHold$5.00View Rating Details
3/6/2015MLV & Co.Set Price TargetBuy$16.00View Rating Details
(Data available from 2/21/2015 forward)

Earnings

Earnings History for Conatus Pharmaceuticals (NASDAQ:CNAT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017        
11/8/2016Q3($0.34)($0.31)ViewListenView Earnings Details
8/3/2016Q216($0.38)($0.30)ViewN/AView Earnings Details
5/5/2016Q116($0.35)($0.35)ViewN/AView Earnings Details
3/9/2016Q4($0.37)($0.30)ViewListenView Earnings Details
11/4/2015Q315($0.38)($0.31)ViewN/AView Earnings Details
8/5/2015Q215($0.34)($0.31)ViewN/AView Earnings Details
5/7/2015Q115($0.38)($0.38)ViewListenView Earnings Details
3/11/2015Q414($0.49)($0.34)ViewListenView Earnings Details
11/12/2014Q3($0.44)($0.42)ViewN/AView Earnings Details
8/13/2014Q214($0.40)($0.34)ViewListenView Earnings Details
5/13/2014Q1($0.33)($0.34)ViewN/AView Earnings Details
3/27/2014($0.27)($0.33)ViewN/AView Earnings Details
11/14/2013Q3($0.20)($0.28)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)
Current Year EPS Consensus Estimate: $-1.22 EPS
Next Year EPS Consensus Estimate: $-0.80 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.44)($0.33)($0.37)
Q2 20163($0.43)($0.35)($0.38)
Q3 20163($0.39)($0.32)($0.36)
Q4 20163($0.37)($0.31)($0.34)
Q1 20171($0.26)($0.26)($0.26)
Q2 20171($0.26)($0.26)($0.26)
Q3 20171($0.26)($0.26)($0.26)
Q4 20171($0.26)($0.26)($0.26)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Conatus Pharmaceuticals (NASDAQ:CNAT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Conatus Pharmaceuticals (NASDAQ:CNAT)
Insider Ownership Percentage: 28.50%
Institutional Ownership Percentage: 15.90%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/8/2015Daniel L KisnerDirectorBuy4,000$5.75$23,000.00View SEC Filing  
7/30/2013David F HaleDirectorBuy2,588$11.00$28,468.00View SEC Filing  
7/30/2013Luke EvninMajor ShareholderBuy165,265$11.00$1,817,915.00View SEC Filing  
7/30/2013Steven J MentoCEOBuy13,800$11.00$151,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Conatus Pharmaceuticals (NASDAQ:CNAT)
DateHeadline
marketexclusive.com logoCONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT) Files An 8-K Departure of Directors or Certain Officers ... - Market Exclusive (NASDAQ:CNAT)
marketexclusive.com - February 20 at 11:47 AM
News IconEye on Technical Levels for Conatus Pharmaceuticals Inc. (CNAT) - Benton Bulletin (NASDAQ:CNAT)
bentonbulletin.com - February 18 at 4:12 PM
streetinsider.com logoConatus Pharmaceuticals (CNAT) CFO Charles J. Cashion to Retire - StreetInsider.com (NASDAQ:CNAT)
www.streetinsider.com - February 18 at 4:12 PM
4-traders.com logoCONATUS PHARMACEUTICALS INC. : Change in Directors or Principal Officers (form 8-K) (NASDAQ:CNAT)
www.4-traders.com - February 17 at 5:49 PM
News IconConatus Pharmaceuticals Sell For 23% Gain In 3 Days (NASDAQ:CNAT)
www.guerillastocktrading.com - February 16 at 4:29 PM
biz.yahoo.com logoCONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fin (NASDAQ:CNAT)
biz.yahoo.com - February 16 at 4:29 PM
News IconStock Checkup: Technical Watch on Conatus Pharmaceuticals Inc. (CNAT) - Baldwin Journal (NASDAQ:CNAT)
baldwinjournal.com - February 13 at 5:02 PM
News IconConatus Pharmaceuticals Inc. (NASDAQ:CNAT) Stock ABR At 1 - Stock Observer (NASDAQ:CNAT)
www.thestockobserver.com - February 10 at 2:47 AM
biz.yahoo.com logoCONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:CNAT)
biz.yahoo.com - February 8 at 4:42 PM
finance.yahoo.com logoConatus Pharmaceuticals Appoints William R. LaRue as Independent Board Member (NASDAQ:CNAT)
finance.yahoo.com - February 7 at 5:29 PM
finance.yahoo.com logoConatus to Present at BIO CEO & Investor Conference (NASDAQ:CNAT)
finance.yahoo.com - February 6 at 4:25 PM
finance.yahoo.com logoConatus Pharmaceuticals Promotes Daniel L. Ripley to Senior Vice President, Business Development, Program and Alliance Management (NASDAQ:CNAT)
finance.yahoo.com - February 2 at 4:45 PM
News IconTechnical Roundup on Shares of Conatus Pharmaceuticals Inc. (CNAT) - Rives Journal (NASDAQ:CNAT)
rivesjournal.com - January 29 at 9:29 PM
News IconHigh Volatility Creating Buzz Mid-Session For Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - Wall Street Beacon (NASDAQ:CNAT)
wsbeacon.com - January 27 at 5:45 PM
News IconStock Spotter: Review on Technical Levels for Conatus Pharmaceuticals Inc. (CNAT) - Sherwood Daily (NASDAQ:CNAT)
sherwooddaily.com - January 26 at 10:33 PM
News IconVolatility Numbers in View for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - The Tribune (NASDAQ:CNAT)
lakecitytribune.com - January 26 at 5:30 PM
News IconStock Seesawing as Volatility Sweeps in on Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - Wall Street Beacon (NASDAQ:CNAT)
wsbeacon.com - January 26 at 5:30 PM
biz.yahoo.com logoCONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Termination of a Material Definitive Agreement (NASDAQ:CNAT)
biz.yahoo.com - January 26 at 5:30 PM
News IconConatus Pharmaceuticals Inc. (NASDAQ:CNAT) Projected EPS At $-0.32 - Stock Observer (NASDAQ:CNAT)
www.thestockobserver.com - January 25 at 10:33 PM
News IconEarnings in Full Force, Analysts Take Aim at Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - Wall Street Beacon (NASDAQ:CNAT)
wsbeacon.com - January 25 at 10:33 PM
News IconConatus Pharmaceuticals Inc CNAT Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CNAT)
www.bioportfolio.com - January 23 at 9:42 PM
News IconInvestor Focus on Shares of Conatus Pharmaceuticals Inc. (CNAT) - Sherwood Daily (NASDAQ:CNAT)
sherwooddaily.com - January 22 at 4:23 PM
News IconAmplified Volatility Spotted in Shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - Wall Street Beacon (NASDAQ:CNAT)
wsbeacon.com - January 19 at 10:37 PM
News IconIndicator Level Review for Conatus Pharmaceuticals Inc. (CNAT) - Sherwood Daily (NASDAQ:CNAT)
sherwooddaily.com - January 19 at 5:37 PM
News IconWill The Needle Move For Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:CNAT)
wsbeacon.com - January 17 at 5:11 PM
finance.yahoo.com logoShort Interest In Conatus Pharmaceuticals Surges (NASDAQ:CNAT)
finance.yahoo.com - January 13 at 5:04 PM
News IconDrilling Down Into the Charts for Conatus Pharmaceuticals Inc. (CNAT) - The USA Commerce (NASDAQ:CNAT)
theusacommerce.com - January 13 at 2:46 AM
us.rd.yahoo.com logoNuVasive at 52-Week High on Preliminary Results, MHLW Nod (NASDAQ:CNAT)
us.rd.yahoo.com - January 12 at 4:44 PM
finance.yahoo.com logoHenry Schein Hurt by Higher Costs, Lacks Growth Drivers (NASDAQ:CNAT)
finance.yahoo.com - January 12 at 4:44 PM
finance.yahoo.com logoCan The Uptrend Continue for Conatus (CNAT)? (NASDAQ:CNAT)
finance.yahoo.com - January 11 at 4:47 PM
News IconThe Top Penny Stocks for January 2017 (NASDAQ:CNAT)
moneymorning.com - January 9 at 5:31 PM
stocksdaily.net logoConatus Pharmaceuticals Inc. (NASDAQ:CNAT) EPS Projection At $-0.32? - Stocks Daily (NASDAQ:CNAT)
www.stocksdaily.net - January 6 at 4:48 PM
News IconConatus Pharmaceuticals Inc (NASDAQ:CNAT) Reports Significant Joint-Venture Deal - Traders350 (NASDAQ:CNAT)
traders350.com - January 6 at 4:48 PM
istreetwire.com logoMomentum Stocks in Focus: Conatus Pharmaceuticals Inc. (CNAT), Sprouts Farmers Market, Inc. (SFM), Hess ... - iStreetWire (NASDAQ:CNAT)
istreetwire.com - January 3 at 12:52 PM
News IconConatus Pharmaceuticals (CNAT) - Research Analysts' Recent Ratings Changes (NASDAQ:CNAT)
prensariotiretail.com - December 31 at 2:51 AM
News IconRecent Analysts' Ratings Changes for Conatus Pharmaceuticals (CNAT) (NASDAQ:CNAT)
myhealthbowl.com - December 29 at 9:47 PM
finance.yahoo.com logoConatus Pharmaceuticals Significant Joint-Venture Review and Analysis of Third Quarter 2016 Results (NASDAQ:CNAT)
finance.yahoo.com - December 29 at 4:45 PM
nasdaq.com logoAre Options Traders Betting on a Big Move in Conatus Pharmaceuticals (CNAT) Stock? - Nasdaq (NASDAQ:CNAT)
www.nasdaq.com - December 28 at 4:26 PM
News IconConatus Pharmaceuticals Inc (NASDAQ:CNAT) Releases Updates On Clinical Development Programs. (NASDAQ:CNAT)
wallstreetpr.com - December 28 at 12:12 PM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Conatus Pharmaceuticals (CNAT) Stock? (NASDAQ:CNAT)
finance.yahoo.com - December 28 at 12:12 PM
marketexclusive.com logoAnalyst Activity – SunTrust Banks Inc. Reiterates Buy on Conatus ... - Market Exclusive (NASDAQ:CNAT)
marketexclusive.com - December 26 at 4:13 PM
marketexclusive.com logoAnalyst Activity – SunTrust Banks Inc. Reiterates Buy on Conatus Pharmaceuticals (NASDAQ:CNAT) (NASDAQ:CNAT)
marketexclusive.com - December 25 at 11:41 AM
4-traders.com logoFriday Sector Leaders: Drugs, Biotechnology Stocks (NASDAQ:CNAT)
www.4-traders.com - December 23 at 4:34 PM
finance.yahoo.com logoOptions Traders Expect Huge Moves in Conatus Pharmaceuticals (CNAT) Stock (NASDAQ:CNAT)
finance.yahoo.com - December 23 at 4:34 PM
capitalcube.com logoConatus Pharmaceuticals, Inc. :CNAT-US: Earnings Analysis: Q3, 2016 By the Numbers : December 23, 2016 (NASDAQ:CNAT)
www.capitalcube.com - December 23 at 4:34 PM
News IconStock in Queue: Kinross Gold Corporation (NYSE:KGC), Conatus ... - The Newburgh Press (NASDAQ:CNAT)
newburghpress.com - December 23 at 2:34 AM
finance.yahoo.com logoCompany News for December 21, 2016 (NASDAQ:CNAT)
finance.yahoo.com - December 21 at 5:04 PM
News IconConatus soars on Novartis deal (NASDAQ:CNAT)
canalcncarauca.com - December 20 at 10:04 PM
News IconConatus Pharmaceuticals Inc. (CNAT) Hits New 52-Week High Following Analyst Upgrade (NASDAQ:CNAT)
www.xboxonezone.com - December 20 at 10:04 PM
finance.yahoo.com logoBanking Sector Leading Rally in U.S. Markets (NASDAQ:CNAT)
finance.yahoo.com - December 20 at 10:04 PM

Social

What is Conatus Pharmaceuticals' stock symbol?

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

Where is Conatus Pharmaceuticals' stock going? Where will Conatus Pharmaceuticals' stock price be in 2017?

7 brokerages have issued 12 month price targets for Conatus Pharmaceuticals' shares. Their forecasts range from $7.00 to $26.00. On average, they expect Conatus Pharmaceuticals' share price to reach $14.80 in the next year.

When will Conatus Pharmaceuticals announce their earnings?

Conatus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.

Who owns Conatus Pharmaceuticals stock?

Conatus Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.73%), United Capital Financial Advisers LLC (0.61%), Ellington Management Group LLC (0.12%) and ING Groep NV (0.08%).

Who bought Conatus Pharmaceuticals stock? Who is buying Conatus Pharmaceuticals stock?

Conatus Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Ellington Management Group LLC, ING Groep NV and United Capital Financial Advisers LLC.

How do I buy Conatus Pharmaceuticals stock?

Shares of Conatus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Conatus Pharmaceuticals stock cost?

One share of Conatus Pharmaceuticals stock can currently be purchased for approximately $5.25.

Conatus Pharmaceuticals (NASDAQ:CNAT) Chart for Tuesday, February, 21, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Earnings History Chart

Earnings by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Dividend History Chart

Dividend Payments by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Last Updated on 2/21/2017 by MarketBeat.com Staff